

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
24 April 2025 (24.04.2025)



(10) International Publication Number  
**WO 2025/083031 A1**

(51) International Patent Classification:

*A61K 31/573* (2006.01)      *A61K 47/40* (2006.01)  
*A61K 9/00* (2006.01)      *A61P 27/02* (2006.01)  
*A61K 9/10* (2006.01)      *A61K 47/69* (2017.01)  
*A61K 47/10* (2017.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/079154

(22) International Filing Date:

16 October 2024 (16.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2023/078697

16 October 2023 (16.10.2023)      EP  
63/544,325      16 October 2023 (16.10.2023)      US

(71) Applicant: **OCULIS OPERATIONS SÀRL** [CH/CH];  
Avenue de la Gare 39, 1003 LAUSANNE (CH).

(72) Inventors: **SHERIF, Riad**; c/o OCULIS OPERATIONS  
SÀRL EPFL Innovation Park Building D, 1015  
LAUSANNE (CH). **MARKABI, Sabri**; C/O OCULIS OP-  
ERATIONS SARL EPFL Innovation Park Building D,  
1015 LAUSANNE (CH). **DUGEL, Pravin**; C/O OCULIS  
OPERATIONS EPFL Innovation Park Building D, 1015  
LAUSANNE (CH).

(74) Agent: **PLASSERAUD IP**, 104 rue de Richelieu CS92104,  
75080 PARIS CEDEX 02 (FR).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: METHOD OF TREATING DIABETIC MACULAR EDEMA

(57) Abstract: The present disclosure relates to a method of treating diabetic macular edema in a human subject in need thereof, said method comprising (i) an induction phase of topically administering to an affected eye of said subject, an eye drop formulation comprising 1.5% (w/v) dexamethasone, at a dosing of 5 to 7 drops a day for 3, 4, 5, 6 weeks, followed by, (ii) a maintenance phase of topically administering to an affected eye of said subject, said eye drop formulation comprising 1.5% (w/v) dexamethasone at a daily dosing less frequent than the induction phase for example 1-3 drops.

WO 2025/083031 A1